|1.||Bergqvist, A: 2 articles (07/2001 - 12/2000)|
|2.||Brown, Julie: 1 article (01/2015)|
|3.||Farquhar, Cynthia: 1 article (01/2015)|
|4.||Brinker, Allen: 1 article (05/2013)|
|5.||Avigan, Mark: 1 article (05/2013)|
|6.||Gatti, Jasmine: 1 article (05/2013)|
|7.||Riggs, M M: 1 article (01/2012)|
|8.||Martin, S W: 1 article (01/2012)|
|9.||van der Graaf, P H: 1 article (01/2012)|
|10.||Bennetts, M: 1 article (01/2012)|
08/01/1994 - "These results show the high efficacy of nafarelin in endometriosis treatment."
05/01/1995 - "A 3-month course of nafarelin provided effective symptom relief for endometriosis. "
02/25/1988 - "We conclude that nafarelin is an effective agent for treating endometriosis and has few side effects other than hypoestrogenism."
06/01/2000 - "Twenty-four-week nafarelin treatment for clinical endometriosis symptoms in women < or = 29 years was safe and effective."
11/01/1994 - "Our purpose was to investigate the efficacy of postsurgical treatment with nafarelin in women with advanced endometriosis. "
11/01/1997 - "The patients' pelvic pain scores dropped significantly in the nafarelin and placebo groups after 6 months of treatment. "
12/01/2000 - "The aim of the work was estimation of effectiveness of Synarel preparation in the treatment of pelvic pain syndrom caused by endometriosis, and assessment of remission of endometriosal focuses, situated in the small pelvis. "
05/01/1995 - "Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain."
11/01/1994 - "This study suggests that medical treatment with nafarelin does not markedly improve pelvic pain and short-term reproductive prognosis in women with stages III and IV endometriosis."
02/01/1990 - "Nafarelin in the treatment of pelvic pain caused by endometriosis."
|3.||Leiomyoma (Uterine Fibroids)
04/01/1990 - "Nafarelin has also been used effectively in in vitro fertilisation programmes, and in hirsute women and those with uterine leiomyoma, particularly to induce preoperative fibroid shrinkage. "
06/01/2000 - "To review the efficacy and safety of nafarelin in the treatment of leiomyomas. "
06/01/2000 - "Clinical use of nafarelin in the treatment of leiomyomas. "
01/01/1990 - "Effect of nafarelin on uterine fibroids measured by ultrasound and magnetic resonance imaging."
04/01/1988 - "Eleven women with uterine leiomyomas were treated with 800 micrograms of nafarelin per day for 6 months. "
12/01/1989 - "Treatment of uterine leiomyomas and hirsutism with nafarelin."
10/01/1986 - "These data demonstrate that by suppressing ovarian androgen production, nafarelin may be useful for the treatment of hirsutism associated with either increased ovarian androgen production or increased sensitivity of the hair follicle to normal concentrations of circulating androgens."
10/01/1986 - "The purpose of this study was to investigate the use of one superactive agonistic GnRH analog, nafarelin, in the treatment of hirsutism. "
10/01/1986 - "Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin)."
07/16/1992 - "Approximately half of women with oligomenorrhea, hirsutism, or acne have an abnormal response to the gonadotropin-releasing hormone agonist nafarelin, suggesting an ovarian cause of their androgen excess."
02/01/1992 - "With nafarelin, hypoestrogenic side effects, such as hot flashes, are more common. "
07/01/1991 - "The most common adverse effect associated with nafarelin therapy is hot flashes. "
02/25/1988 - "These changes were not observed in nafarelin users, but a higher percentage of them reported hot flashes and decreased libido. "
12/01/1999 - "Nafarelin was associated with significantly fewer days with moderate or severe hot flashes than leuprolide during treatment (P < .05) and with significantly fewer moderate or severe hypoestrogenic symptoms overall at three months of treatment (P < .05). "
02/01/1990 - "Assessments of severity of symptoms, laparoscopic scores before and after therapy, and pregnancy rates showed that nafarelin, 400 and 800 micrograms administered intranasally, was as efficacious as oral danazol, 600 and 800 mg. The adverse effects seen with nafarelin, mainly hot flashes, were related to its mode of action, namely hypoestrogenemia induced by reversible inhibition of ovarian hormone production. "
|1.||Gonadotropin-Releasing Hormone (GnRH)